Summary by Futu AI
Medtronic Inc., a subsidiary of Medtronic plc, issued €3 billion in senior notes across four tranches on June 3, 2024. The offering includes €850M of 3.650% notes due 2029, €850M of 3.875% notes due 2036, €600M of 4.150% notes due 2043, and €700M of 4.150% notes due 2053. The company expects to receive net proceeds of approximately €2.97B after deducting underwriting discounts and expenses.The notes are fully guaranteed by Medtronic Global Holdings S.C.A. and Medtronic plc, ranking equally with other unsecured senior indebtedness. The proceeds will be used for general corporate purposes, including repayment of outstanding commercial paper and other debt. The notes will be listed on the New York Stock Exchange.Each series of notes includes redemption provisions allowing early redemption at specified prices before their respective Par Call Dates. After the Par Call Dates, the notes can be redeemed at 100% of principal plus accrued interest. The financial impact of this offering was incorporated into Medtronic's fiscal year 2025 adjusted EPS guidance announced on May 23, 2024.